Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines

Vaccine

Volumn 31, Issue 51, 2013, Pages 6097-6106

  Tunheim, G ^a   Arnemo, M ^a   Naess L M ^a   Fjeldheim, A K ^a   Nome, L ^a   Bolstad, K ^a   Aase, A ^a   Mandiarote, A ^b   Gonzalez H ^b   Gonzalez D ^b   Garcia L ^b   Cardoso, D ^b   Norheim, G ^a   Rosenqvist, E ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b FINLAY INSTITUTE   (Cuba)

Author keywords

Africa; Meningitis belt; Meningococcal disease; Neisseria meningitidis; OMV; OPA; Opsonophagocytic activity; Outer membrane protein; Outer membrane vesicle; SBA; Serum bactericidal activity; Vaccine

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; POLYSACCHARIDE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; MEMBRANE VESICLE; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; OUTER MEMBRANE; PRIORITY JOURNAL; SERUM BACTERICIDAL ACTIVITY;

AFRICA; MENINGITIS BELT; MENINGOCOCCAL DISEASE; NEISSERIA MENINGITIDIS; OMV; OPA; OPSONOPHAGOCYTIC ACTIVITY; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE VESICLE; SBA; SERUM BACTERICIDAL ACTIVITY; VACCINE;

ANIMALS; ANTIBODIES, BACTERIAL; DRUG EVALUATION, PRECLINICAL; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS, SEROGROUP A; NEISSERIA MENINGITIDIS, SEROGROUP W-135; VACCINES, CONJUGATE;

EID: 84888433580     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.044     Document Type: Article

References (41)

1. Lapeyssonnie L. Cerebrospinal meningitis in Africa. Bulletin of the World Health Organization 1963, 28(Suppl.):1-114.
2. LaForce F.M., Ravenscroft N., Djingarey M., Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009, 27(Suppl. 2):B13-B19.
3. Delrieu I., Yaro S., Tamekloe T.A., Njanpop-Lafourcade B.M., Tall H., Jaillard P., et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLOS ONE 2011, 6:e19513.
4. Harrison L.H. Prospects for vaccine prevention of meningococcal infection. Clinical Microbiology Reviews 2006, 19:142-164.
5. Greenwood B.M., Hassan-King M., Whittle H.C. Prevention of secondary cases of meningococcal disease in household contacts by vaccination. British Medical Journal 1978, 1:1317-1319.
6. Frasch C.E., Preziosi M.P., LaForce F.M. Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM). Human Vaccines & Immunotherapeutics 2012, 8:715-724.
7. Sow S.O., Okoko B.J., Diallo A., Viviani S., Borrow R., Carlone G., et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. The New England Journal of Medicine 2011, 364:2293-2304.
8. Hirve S., Bavdekar A., Pandit A., Juvekar S., Patil M., Preziosi M.P., et al. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial. Vaccine 2012, 30:6456-6460.
9. Kristiansen P.A., Diomande F., Ba A.K., Sanou I., Ouedraogo A.S., Ouedraogo R., et al. Impact of the serogroup A meningococcal conjugate vaccine. MenAfriVac, on carriage and herd immunity. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2013, 56:354-363.
10. Novak R.T., Kambou J.L., Diomande F.V., Tarbangdo T.F., Ouedraogo-Traore R., Sangare L., et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. The Lancet Infectious Diseases 2012, 12:757-764.
11. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(Suppl. 2):B3-B12.
12. Holst J., Oster P., Arnold R., Tatley M.V., Næss L.M., Aaberge I.S., et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Human Vaccines & Immunotherapeutics 2013, 9:1241-1253.
13. Norheim G., Tunheim G., Naess L.M., Kristiansen P.A., Caugant D.A., Rosenqvist E. An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt. Scandinavian Journal of Immunology 2012, 76:99-107.
14. Norheim G., Rosenqvist E., Aseffa A., Yassin M.A., Mengistu G., Kassu A., et al. Characterization of Neisseria meningitidis isolates from recent outbreaks in Ethiopia and comparison with those recovered during the epidemic of 1988 to 1989. Journal of Clinical Microbiology 2006, 44:861-871.
15. Comanducci M., Bambini S., Brunelli B., Adu-Bobie J., Arico B., Capecchi B., et al. NadA, a novel vaccine candidate of Neisseria meningitidis. The Journal of Experimental Medicine 2002, 195:1445-1454.
16. Romeu B., Lastre M., Garcia L., Cedre B., Mandariote A., Farinas M., et al. Combined meningococcal serogroup A and W outer-membrane vesicles activate cell-mediated immunity and long-term memory responses against non-covalent capsular polysaccharide A. Immunologic Research 2013, [Epub ahead of print].
17. Frasch C.E., van Alphen L., Holst J., Poolman J.T., Rosenqvist E. Outer membrane protein vesicle vaccines for meningococcal disease. Methods in Molecular Medicine 2001, 66:81-107.
18. Tsai C.M., Frasch C.E., Rivera E., Hochstein H.D. Measurements of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage. Journal of Biological Standardization 1989, 17:249-258.
19. Carlone G.M., Frasch C.E., Siber G.R., Quataert S., Gheesling L.L., Turner S.H., et al. Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay. Journal of Clinical Microbiology 1992, 30:154-159.
20. Norheim G., Aseffa A., Yassin M.A., Mengistu G., Kassu A., Fikremariam D., et al. Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci. Clinical and Vaccine Immunology 2008, 15:863-871.
21. Wedege E. Immunoblot analysis of sera from patients and vaccinees. Methods in Molecular Medicine 2001, 66:275-288.
22. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clinical and Diagnostic Laboratory Immunology 1997, 4:156-167.
23. Aase A., Naess L.M., Sandin R.H., Herstad T.K., Oftung F., Holst J., et al. Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine 2003, 21:2042-2051.
24. Garcia L., Mandiarote A., Norheim G., Gonzalez D., Reyes G., Tunheim G. P227 Scale-up of process for GMP production of a serogroup A and W135 meningococcal outer membrane vesicle vaccine for Africa [abstract]. 17th international pathogenic conference 2010, [accessed 10.09.2013]. http://neisseria.org/ipnc/2010/IPNC_2010_abstracts.pdf.
25. Reyes G.A., Mandiarote A., Tunheim G., Gonzalez D., Norheim G., Cedre B., et al. P229 characterization and immunogenicity evaluation of serogroup A and W135 outer membrane vesicles derived from growth in modified Frantz and Catlin medium [abstract]. 17th international pathogenic conference 2010, [accessed 10.09.13]. http://neisseria.org/ipnc/2010/IPNC_2010_abstracts.pdf.
26. Norheim G., Aase A., Caugant D.A., Hoiby E.A., Fritzsonn E., Tangen T., et al. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine 2005, 23:3762-3774.
27. Borrow R., Balmer P., Miller E. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 2005, 23:2222-2227.
28. Fredriksen J.H., Rosenqvist E., Wedege E., Bryn K., Bjune G., Froholm L.O., et al. Production, characterization and control of MenB-vaccine Folkehelsa: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Annals 1991, 14:67-79. discussion 80.
29. Lee C.H., Kuo W.C., Beri S., Kapre S., Joshi J.S., Bouveret N., et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine 2009, 27:726-732.
30. Costantino P., Viti S., Podda A., Velmonte M.A., Nencioni L., Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 1992, 10:691-698.
31. Thornton V., Lennon D., Rasanathan K., O'Hallahan J., Oster P., Stewart J., et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 2006, 24:1395-1400.
32. Assessment report for menveo common name: meningococcal group A, C, W135 and Y conjugate vaccine procedure no. EMEA/H/C/001095 assessment report 2009, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001095/WC500090150.pdf [accessed 10.09.13].
33. Norheim G., Arne Hoiby E., Caugant D.A., Namork E., Tangen T., Fritzsonn E., et al. Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease. Vaccine 2004, 22:2171-2180.
34. Findlow J., Borrow R., Snape M.D., Dawson T., Holland A., John T.M., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2010, 51:1127-1137.
35. Moran E.E., Burden R., Labrie J.E., Wen Z., Wang X.M., Zollinger W.D., et al. Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine. Clinical and Vaccine Immunology: CVI 2012, 19:659-665.
36. Hong E., Giuliani M.M., Deghmane A.E., Comanducci M., Brunelli B., Dull P., et al. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?. Vaccine 2013, 31:1113-1116.
37. Xie O., Pollard A., Mueller J.E., Norheim G. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine 2013, 31:2852-2861.
38. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., Dykes J., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA: The Journal of the American Medical Association 1999, 281:1520-1527.
39. Nicolas P., Norheim G., Garnotel E., Djibo S., Caugant D.A. Molecular epidemiology of Neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. Journal of Clinical Microbiology 2005, 43:5129-5135.
40. Caugant D.A., Kristiansen P.A., Wang X., Mayer L.W., Taha M.K., Ouedraogo R., et al. Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLOS ONE 2012, 7:e46019.
41. Pajon R., Fergus A.M., Koeberling O., Caugant D.A., Granoff D.M. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Neglected Tropical Diseases 2011, 5:e1302.